The Role of Neprilysin Inhibitors in Cardiovascular Disease

Related Experiment Video

Updated: Mar 31, 2026

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

17.2K

Jared Mills1, Orly Vardeny2,3

  • 1University of Wisconsin School of Pharmacy (J.M., O.V.), Madison, WI, USA.

Current Heart Failure Reports
|October 16, 2015
PubMed

Insights

Sacubitril/valsartan, a novel heart failure medication, significantly reduced cardiovascular death and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF). This new drug offers improved survival rates for HFrEF patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Heart failure impacts millions annually, causing significant morbidity, mortality, and healthcare costs.
  • Existing treatments like RAAS and SNS blockers have limitations, with 5-year survival rates remaining low.
  • New therapeutic targets and drugs are crucial for improving heart failure outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of LCZ696 (sacubitril/valsartan) in patients with heart failure.
  • To assess the impact of sacubitril/valsartan on cardiovascular mortality and heart failure hospitalizations.
  • To explore the potential of sacubitril/valsartan in both HFrEF and HFpEF populations.

Main Methods:

  • The PARADIGM-HF study compared LCZ696 (sacubitril/valsartan) against enalapril in patients with HFrEF.
  • Participants were on guideline-directed medical therapies.
  • Outcomes included a composite of cardiovascular mortality and heart failure hospitalizations.

Main Results:

  • LCZ696 (sacubitril/valsartan) significantly reduced the composite endpoint compared to enalapril.
  • The study demonstrated prolonged survival in the treatment group.
  • Hypotension was a more frequent adverse event with LCZ696 (sacubitril/valsartan) than with ACE inhibitors.

Conclusions:

  • Sacubitril/valsartan is a promising new treatment for HFrEF, improving clinical outcomes and survival.
  • Careful dose titration is necessary due to increased risk of hypotension.
  • Further clinical studies will elucidate long-term tolerability across diverse patient demographics.

Keywords:
Angiotension IICardiovascular mortalityHFpEFHFrEFHeart failureNatriuretic peptide levelsNeprilysin inhibitor

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.8K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.5K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
608
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K